ADJUVANT ORAL RAZOXANE (ICRF-159) IN RESECTABLE COLORECTAL-CANCER

被引：0
|
作者：
GILBERT, JM
HELLMANN, K
EVANS, M
CASSELL, PG
STOODLEY, B
ELLIS, H
WASTELL, C
机构：
[1] WEXHAM PK HOSP,SLOUGH,ENGLAND
[2] WESTMINSTER HOSP,LONDON SW1P 2AP,ENGLAND
[3] IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND
[4] EASTBOURNE DIST HOSP,EASTBOURNE,ENGLAND
来源：
CANCER CHEMOTHERAPY AND PHARMACOLOGY | 1982年 / 8卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：293 / 299
页数：7
相关论文
共 50 条
  • [31] PHASE I-II EVALUATION OF RAZOXANE (ICRF-159) AND DOXORUBICIN IN GASTROINTESTINAL CANCER - A SOUTHEASTERN CANCER STUDY-GROUP TRIAL
    DESIMONE, PA
    GRECO, FA
    OMURA, GA
    BARTOLUCCI, A
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1986, 9 (03): : 185 - 186
  • [32] ICRF-159 IN ADVANCED GASTRIC-CANCER - ABSENCE OF ACTIVITY
    KRASNOW, S
    BUNN, PA
    IHDE, DC
    MATTHEWS, MJ
    COHEN, MH
    EDDY, J
    MINNA, JD
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1982, 5 (06): : 635 - 639
  • [33] ICRF-159 (RAZOXANE) IN PATIENTS WITH ADVANCED SQUAMOUS-CELL CARCINOMA OF THE UTERINE CERVIX - FOR THE GYNECOLOGIC ONCOLOGY GROUP
    CONROY, JF
    LEWIS, GC
    BLESSING, JA
    MANGAN, C
    HATCH, K
    WILBANKS, G
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1984, 7 (02): : 131 - 133
  • [34] PHASE-III TRIAL OF RAZOXANE (ICRF-159) VS 5-FLUOROURACIL (5-FU) IN ADVANCED METASTATIC COLORECTAL-CARCINOMA
    PAUL, AR
    ENGSTROM, PF
    CATALANO, RB
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1979, 20 (MAR): : 311 - 311
  • [35] EFFECT OF RAZOXANE ON METASTASES FROM COLORECTAL-CANCER
    HELLMANN, K
    GILBERT, J
    EVANS, M
    CASSELL, P
    TAYLOR, R
    CLINICAL & EXPERIMENTAL METASTASIS, 1987, 5 (01) : 3 - 8
  • [36] ICRF-159 (RAZOXANE) IN PATIENTS WITH ADVANCED NONSQUAMOUS CELL-CARCINOMA OF THE CERVIX - A GYNECOLOGIC-ONCOLOGY-GROUP STUDY
    HOMESLEY, HD
    BLESSING, JA
    BERMAN, M
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1986, 9 (04): : 325 - 326
  • [37] PHASE-II TRIAL OF RAZOXANE (ICRF-159) IN PREVIOUSLY TREATED PATIENTS WITH HEAD AND NECK SQUAMOUS-CELL CARCINOMA
    SHAH, MK
    CATALANO, RB
    ENGSTROM, PF
    BELLET, RE
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1979, 20 (MAR): : 366 - 366
  • [38] POTENTIATION OF RADIATION EFFECTS BY RAZOXANE (ICRF 159) IN HUMAN-TUMOR CELLS OF COLORECTAL ORIGIN
    CHAPMAN, IV
    YUSOF, N
    RADIATION RESEARCH, 1981, 87 (02) : 419 - 419
  • [39] DOUBLE-BLIND CONTROLLED CLINICAL-TRIAL OF RADIATION PLUS RAZOXANE (ICRF-159) VERSUS RADIATION PLUS PLACEBO IN TREATMENT OF HEAD AND NECK CANCER
    BAKOWSKI, MT
    MACDONALD, E
    MOULD, RF
    CAWTE, P
    SLOGGEM, J
    BARRETT, A
    DALLEY, V
    NEWTON, KA
    WESTBURY, G
    JAMES, SE
    HELLMANN, K
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1978, 4 (1-2): : 115 - 119
  • [40] PHASE-II STUDY OF ICRF-159 IN REFRACTORY METASTATIC BREAST-CANCER
    CREECH, RH
    ENGSTROM, PF
    HARRIS, DT
    CATALANO, RB
    BELLET, RE
    CANCER TREATMENT REPORTS, 1979, 63 (01): : 111 - 114
12345